To date, my laboratory has identified human papillomavirus to be a cause of head and neck cancer, and we are now focused on how we can improve the prevention, diagnosis and treatment of these cancers.
In the clinic, we tailor our therapy to the individual patient to minimize the risk of therapy while trying to achieve the best possible outcomes. We have numerous clinical trials designed to investigate novel therapies, with a goal toward improving cure rates while reducing the toxicity of therapy.
Johns Hopkins University School of Medicine
Massachusetts General Hospital
7/1/1993 - 6/30/1995
Specialties and conditions I treat
- Medical Oncology
- Head and Neck Cancer
Locations where I practice
More about my work
Johns Hopkins Hospital
7/1/1996 - 2/29/2000
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
News about me
- Prominent National Organization Honors Prolific Ohio State Scientist Physician
- Prominent National Organization Honors Prolific Ohio State Scientist, Physician
- Nivolumab Improved Survival For Patients With Head and Neck Squamous Cell Carcinoma
- Ohio State Receives Top Rating From National Cancer Institute — ‘Exceptional’ — Re-Designated As Comprehensive Cancer Center
- Experience Counts with Radiation Therapy for Head and Neck Cancer Study Shows
- HPV Can Damage Genes and Chromosomes Directly, Sequencing Study Shows
- JEGS Foundation Donates $10 Million To New Cancer Hospital At Ohio State
- Oral HPV Infection is Three Times More Common in Men than Women, Study Shows
- Tumor Virus Is Best Predictor Of Throat Cancer Survival
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Gillison has reported financial relationships with the medical device, research and/or drug companies listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office at 614-293-7802.
- Bristol-Myers Squibb